Health
Entresto’s effect ‘unclear’ in advanced chronic heart failure: study – Korea Biomedical Review
Novartis’ Entresto (ingredient: sacubitril/valsartan), an angiotensin receptor-neprilysin inhibitor (ARNI), has become the standard…
Novartis’ Entresto (ingredient: sacubitril/valsartan), an angiotensin receptor-neprilysin inhibitor (ARNI), has become the standard therapy for heart failure with reduced ejection fraction (HFrEF).
However, a recent study showed that the treatment did not…
Continue Reading
-
Noosa News24 hours agoAustralian growers expect to benefit from US tariffs as Trump’s trade war angers markets
-
Noosa News21 hours agoDisaster relief packages announced for flood-stricken western Queensland
-
Noosa News24 hours agoHow to get the most from potted citrus and when they’ll fruit
-
General23 hours agoPeter Dutton partially walks back public service work-from-home vow